## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.3% below STRENGTH zone (4.0-10.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($137.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Who Owns Agilent Technologies? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260104T130726 | Neutral | Relevance: 100%
- This article details the top institutional shareholders of Agilent Technologies (NYSE: A), highlighting major passive and active investors. It also reviews recent insider trades, noting that executives and directors have made small sales, which appear to be for personal portfolio management rather than signaling a negative outlook. The overall picture suggests Agilent remains a stable, institutionally supported business.

**2. Agilent Technologies (NYSE:A) Upgraded at Evercore ISI**
- Source: MarketBeat | 20260105T135750 | Bullish | Relevance: 100%
- Agilent Technologies (NYSE:A) has been upgraded by Evercore ISI from "in-line" to "outperform" with a $160 price target, suggesting a 16% upside. The company recently surpassed its earnings expectations, reporting $1.59 EPS against $1.58 expected and $1.86B in revenue, and has issued optimistic guidance for Q1 and FY 2026. Despite some insider selling, institutional investors like Arrowstreet Capital have significantly increased their stakes in the medical research company.

**3. Penobscot Investment Management Company Inc. Sells 8,029 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20260104T122049 | Somewhat-Bullish | Relevance: 99%
- Penobscot Investment Management Company Inc. reduced its stake in Agilent Technologies (NYSE:A) by 38.5%, selling 8,029 shares and holding 12,846 shares valued at approximately $1.65 million. This divestment comes as Agilent Technologies reported strong quarterly earnings, beating estimates with $1.59 EPS and $1.86 billion in revenue, and subsequently raised its quarterly dividend. Analysts maintain a "Moderate Buy" consensus for Agilent, with an average target price near $161.77.

**4. Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus**
- Source: ts2.tech | 20260105T202149 | Somewhat-Bullish | Relevance: 69%
- Thermo Fisher Scientific Inc. shares rose about 2.4% after Evercore ISI raised its price target to $650 from $610, maintaining an "outperform" rating. The stock's performance places it in focus ahead of its late-January earnings report, where investors will seek insights into drugmaker and laboratory spending trends. The company's upcoming results will also provide updates on its China market exposure, its acquisition of Clario, and overall demand trends for lab tools and services.

**5. Thermo Fisher stock jumps 2% to start 2026 as investors turn to Jan. 29 earnings**
- Source: ts2.tech | 20260103T015133 | Somewhat-Bullish | Relevance: 63%
- Thermo Fisher Scientific Inc (NYSE: TMO) shares rose 2.25% on the first trading day of 2026, outpacing the S&P 500. This outperformance comes as investors adopt a "buy the dip, sell the rip" mentality after a late-December market slide. All eyes are now on the company's Q4 and full-year 2025 earnings report scheduled for January 29, which will provide crucial insights into demand and the outlook for 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $160 | $155 | +3% |
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | up | Outperform |
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +5.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 21.8x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.5B |
| Beta | 1.29 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 21.8 |
| Current P/E | 24.0 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.0% to 2.3% (+5.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.7pp (needs >4.0% for momentum thesis). MRS_5 at 3.0% confirms short-term momentum alignment. RSI neutral at 55. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.27% (CS: 66) | Neutral |
| RSI_14 | 54.7 | Neutral |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 1.142x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $142.93
- **Stop Loss:** $137.33 (3.9% risk)
- **Target:** $148.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 154
- **Position Value:** $22,011.22
- **Portfolio %:** 22.01%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*